Portnoy Law Firm Announces Class Action on Behalf of LifeMD, Inc. Investors

LOS ANGELES, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises LifeMD, Inc., (“LifeMD” or the "Company") (NASDAQ: LFMD) investors off a class action on behalf of investors that bought securities between May 7, 2025 and August 5, 2025, inclusive (the “Class Period”). LifeMD investors have until October 27, 2025 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/lifemd-inc/. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

On August 5, 2025, LifeMD announced its second quarter 2025 results. Among other items, the Company revealed that higher customer acquisition costs pressured its business during the June quarter. Specifically, LifeMD spent 5% to 25% more to drive new customers to its RexMD platform— a telehealth platform focusing on men’s health—in the second quarter compared to the first. In reacting to this announcement, a KeyBanc Capital Markets analyst stated that LifeMD “took its eye off the ball” in managing customer acquisition costs for RexMD amid its “enormous transition” in the quarter into the weight management space. On this news, Fluor’s stock price fell $5.31 per share, or 44.84%, to close at $6.53 per share on August 6, 2025.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.